McKesson Corp (MCK) Stock AnalysisMCKStock AnalysisMcKesson Corp

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

McKesson Corp is a good buy right now due to its strong recent performance and positive growth outlook. The current price is $893.39, with a 1-year change of +29.17%, indicating significant appreciation over the past year. Additionally, the forward P/E ratio is 20.16, suggesting reasonable valuation compared to growth prospects. The acquisition of Precision Medicine Group for $2.25 billion is expected to enhance its market position, although insider selling has increased by 144.45%, which is a risk to consider.

14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.